Top

Published in:

01-12-2007 | Pediatric Oncology

L1 Is Associated With Favorable Outcome in Neuroblastomas in Contrast to Adult Tumors

Authors: Robin Wachowiak, MD, Henning C. Fiegel, MD, Jussuf T. Kaifi, MD, Alexander Quaas, MD, Annika Krickhahn, MS, Paulus G. Schurr, MD, Rudolf Erttmann, MD, Melitta Schachner, PhD, Dietrich Kluth, MD, Guido Sauter, MD, Jakob R. Izbicki, MD

Published in: Annals of Surgical Oncology | Issue 12/2007

Abstract

Background

Neuroblastoma is the most common solid tumor in childhood with unconventional clinical behavior. L1, a neuronal cell adhesion molecule, is associated with poor survival in malignant adult tumors. The aim of the current study was to determine expression of L1 in pediatric neuroblastoma.

Methods

L1 expression was assessed on a tissue microarray with 66 surgically resected neuroblastoma samples by immunohistochemistry with a monoclonal antibody and peroxidase method. Additionally, mRNA expression was analyzed by reverse transcriptase–polymerase chain reaction with L1-specific primers. Data were correlated survival data by log rank test and Cox regression multivariate analysis.

Results

L1 was detected in 57 (86%) of 66 neuroblastomas, whereas 9 (14%) were L1 negative. Median survival of all children was 72 months. Analysis with Kaplan-Meier method revealed a surprising and contrary finding to adult tumor entities: an association of L1 positivity with better event-free and overall survival (P < .001 and P < .01 by log rank test). Multivariate Cox regression analysis showed an independent prognostic impact of L1 negativity for event-free and overall survival of the children (P < .05).

Conclusions

In contrast to adult tumor entities, where L1 is associated with aggressive clinical behavior, our data show that L1 predicts good outcome in children with neuroblastoma. This novel finding suggests an inverse role of L1 in neuroblastoma. Future studies might focus on the molecular basis of the varying effect of L1 in different tumors.

Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003;8:278–92PubMedCrossRef

Evans AE, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976;44:49–54PubMed

Haas D, Albin AR, Miller C. Complete pathologic maturation and regression of IVS neuroblastoma without treatment. Cancer 1988;62:818–25PubMedCrossRef

Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165–73PubMedCrossRef

Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–77PubMed

Evans AE, D’Angio GJ, Propert K, et al. Prognostic factors in neuroblastoma. Cancer 1987;59:1853–9PubMedCrossRef

Shimada H, Ambros IM, Dehner LP, et al. The international Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364–72PubMedCrossRef

Berthold, Hero B, Simon T, Faldum A, and the “Gesellschaft für Pädiatrische Onkologie und Hämatologie.” NB2004 trial protocol for risk adapted treatment of children with neuroblastomas. Köln, Germany, September 2004

Riley RD, Heney D, Jones DR, et al. A systematic review of molecular and biological markers in neuroblastoma. Clin Cancer Res 2004;10:4–12PubMedCrossRef

10.

Ohnishi T, Matsumura H, Izumoto S, et al. A novel model of glioma cell invasion using organotypic brain slice culture. Cancer Res 1998;58:2935–40PubMed

11.

Schachner M. Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 1997;9:627–34PubMedCrossRef

12.

Brummendorf T, Kenwrick S, Rathjen FG. Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations. Curr Opin Neurobiol 1998;8:87–97PubMedCrossRef

13.

Hortsch M. The L1 family of neural cell adhesion molecules: old proteins performing new tricks. Neuron 1996;17:587–93PubMedCrossRef

14.

Gutwein P, Oleszewski M, Mechtersheimer S, et al. Role of Src kinases in the ADAM-mediated release of L1 adhesion molecule from human tumor cells. J Biol Chem 2000;275:15490–7PubMedCrossRef

15.

Linnemann D, Raz A, Bock E. Differential expression of cell adhesion molecules in variants of K1735 melanoma cells differing in metastatic capacity. Int J Cancer 1989;43:709–12PubMedCrossRef

16.

Fogel M, Mechtersheimer S, Huszar M, et al. L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett 2003;189:237–47PubMedCrossRef

17.

Gil OD, Sakurai T, Bradley AE, et al. Ankyrin binding mediates L1CAM interactions with static components of the cytoskeleton and inhibits retrograde movement of L1CAM on the cell surface. J Cell Biol 2003;162:719–30PubMedCrossRef

18.

Miyahara R, Tanaka F, Nakagawa T, et al. Expression of neural cell adhesion molecules (polysialylated form of neural cell adhesion molecule and L1-cell adhesion molecule) on resected small cell lung cancer specimens: in relation to proliferation state. J Surg Oncol 2001;77:49–54PubMedCrossRef

19.

Fogel M, Gutwein P, Mechtersheimer S, et al. L1 expression as a predictor of progression and survival in children with uterine and ovarian carcinomas. Lancet 2003;362:869–75PubMedCrossRef

20.

Thies A, Schachner M, Moll I, et al. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 2002;38:1708–16PubMedCrossRef

21.

Deichmann M, Kurzen H, Egner U, et al. Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). J Cutan Pathol 2003;30:363–8PubMedCrossRef

22.

Kaifi JT, Zinnkann U, Yekebas EF, et al. L1 cell adhesion molecule (CD171) as a potential marker for poorly differentiated neuroendocrine pancreatic carcinomas. World J Gastroenterol 2006;12:94–8PubMed

23.

Kaifi JT, Strelow A, Schurr PG, et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 2006;19:399–406PubMedCrossRef

24.

Allory Y, Matsuoka Y, Bazille C, et al. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res 2005;11:1190–7PubMed

25.

Euer NI, Kaul S, Deissler H, et al. Identification of L1 CAM, Jagged 2 and Neuromedin U as ovarian cancer–associated antigens. Oncol Rep 2005;13:375–87PubMed

Title: L1 Is Associated With Favorable Outcome in Neuroblastomas in Contrast to Adult Tumors
Authors: Robin Wachowiak, MD
Henning C. Fiegel, MD
Jussuf T. Kaifi, MD
Alexander Quaas, MD
Annika Krickhahn, MS
Paulus G. Schurr, MD
Rudolf Erttmann, MD
Melitta Schachner, PhD
Dietrich Kluth, MD
Guido Sauter, MD
Jakob R. Izbicki, MD
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9608-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

L1 Is Associated With Favorable Outcome in Neuroblastomas in Contrast to Adult Tumors

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2007

Preoperative Portal Vein Embolization and Surgical Resection in Patients with Hepatocellular Carcinoma and Small Future Liver Remnant Volume: Comparison with Transarterial Chemoembolization

Cell Cycle Regulators Show Diagnostic and Prognostic Utility for Differentiated Thyroid Cancer

Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?

Do Very Young Korean Breast Cancer Patients Have Worse Outcomes?

Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy

Combined Hepatectomy and Radiofrequency Ablation for Multifocal Hepatocellular Carcinomas: Long-term Follow-up Results and Prognostic Factors